Disclosures. Questions. A Developmental Approach. Goals and objectives 4/3/2018 FEARS AND TEARS: TREATING ANXIETY AND DEPRESSION IN PRIMARY CARE
|
|
- Baldric McCarthy
- 6 years ago
- Views:
Transcription
1 Disclosures FEARS AND TEARS: TREATING ANXIETY AND DEPRESSION IN PRIMARY CARE I have no financial interests I WILL be talking about non FDA approved uses of medications for anxiety and depression in children and adolescents Elizabeth Reeve MD HealthPartners Medical Group Questions Elizabeth.A.Reeve@HealthPartners.com Goals and objectives A Developmental Approach Review symptoms and presentation of anxiety and depression Develop an understanding of when to refer for therapy, when to start medications, and when to do both Be comfortable with prescribing 2 different, bupropion, and venlafaxine Risks for depression and anxiety start BEFORE conception Genetics of parents Genes that increase risk for depression Genes that code for drug metabolism, receptor and transporter differences Risks in utero Epigenetics The study of heritable changes in gene function that do not involve change in the genetic code itself Felt to be due to environmental stress Toxic exposures Alcohol Childhood Early life adversity 1
2 Serotonin Transporter and Receptor Differences Serotonin transporter (SERT or 5-HTT) is also know as the sodium dependent serotonin transporter The protein involved is coded by the SLC6A4 gene The transport of serotonin by the SERT protein terminates the action of serotonin and recycles it A repeat polymorphism in the promoter of this gene may impact serotonin transport The short form polymorphism may predict a decrease in the response to serontonergic acting antidepressants and may increase the risk of depression when exposed to adverse events Serotonin Transporter and Receptor Differences Rs6295 (HTR1A) a single nucleotide polymorphism (SNP) C and G variations C allele has been found in some cases to be associated with a better response to antidepressants G allele may incur an increased risk for depression CC genotype has also been associated with an increase change of love (SNPedia) To Make it More Confusing Other concepts and characteristics impact risk Resilience Optimism Humor Cognitive flexibility Exposure to positive role models Involvement with religion Attachment Temperament Strange Situation Procedure (Ainsworth) Studies using this paradigm have shown that preschool children of mothers with anxiety are more likely to be insecurely attached Insecurely attached preschoolers had more anxiety disorders later in childhood and adolescence. Caspi et al. (1995) Longitudinal study of 800 children over a twelve year period Boys who were confident and eager to explore new situations at age five had lower rates of anxiety Girls who were passive and shy at ages 3-5 years had higher rates of anxiety 2
3 Consequences of Maternal Depression Prenatal Inadequate prenatal care, poor nutrition, higher preterm birth, low birth weight, pre-eclampsia and spontaneous abortion Infant Anger and protective style of coping, passivity, withdrawal, dysregulated attention and arousal, lower cognitive performance Toddler Passive noncompliance, less mature expression of autonomy, internalizing and externalizing problems, lower interaction, less creative play and lower cognitive performance School age Impaired adaptive functioning, internalizing and externalizing problems, affective disorders, anxiety disorders and conduct disorders, attention deficit/hyperactivity disorder and lower IQ scores Adolescent Affective disorders (depression), anxiety disorders, phobias, panic disorders, conduct disorders, substance abuse and alcohol dependence, attention deficit/hyperactivity disorder and learning disorders Why are these Factors so Important? Helps to understand that the road to each person s depression or anxiety is different This may explain some of the lack of predictability to medical treatment and why antidepressants have such a variable response Normal Anxiety Developmental stages with increased anxiety Stranger anxiety Separation Boogie man Perfectionism Rules Looks/Body image/grooming Common fears Normal Depression Sadness Loss, grief, disappointment Loneliness Overwhelmed Situational stress New school, friends, significant others Onset of symptoms Depression starts as a change in the level of functioning Some depression becomes chronic but not most You are not born depressed Consider temperament, and environmental stress The onset of anxiety is usually more insidious Generalized anxiety, Social anxiety, OCD PTSD and Panic disorder may be more abrupt 3
4 Level of functioning Mild, moderate, severe Assess change based on the individuals previous level of functioning, based on objective data Consider a wide range of activities: friendships, academics, sports, clubs, family life, spiritual life The lower the baseline function the harder it is to measure change Always consider the presence of a precipitating stress Always get collaborative data Mild: symptoms are not obvious to others, and are discovered only on interview Moderate: symptoms are visible to others and cause dysfunction in at least one area of life Severe: symptoms are obvious to others and impair multiple spheres of life How Do Anxious Children Present? If severely disordered may be obvious Rituals may be obvious in OCD School refusal Mutism More subtle symptoms: Frequent trips to the nurse Missed days of school Poor socialization Below expected academic performance Symptoms of anxiety in childhood Separation anxiety Temper tantrums on separation, calling/texting when apart, need to know schedules Generalized anxiety Worry, reassurance seeking, physical symptoms Social anxiety Avoidance of groups, avoids public restrooms, won't talk to strangers (ask for help, pay in a store, order food in a restaurant), avoids performance, may not eat in public OCD Reassurance seeking, washing, counting, checking, control, need for sameness How do Depressed Children Present Young children may not be able to express feelings of sadness Will be irritable, difficult to soothe, poor with transitions, clingy, developmental regression School age children may have increased somatic issues Sleeping, appetite, aches and pains, changes in bowel and bladder function Middle school children may have more academic impact, drop out of activities Adolescents Changes in peer group, avoidance of family, acting out DSM Depression Must have depressed mood or loss of interest or pleasure Must have four more symptoms Must ALL be present for two weeks Must cause functional impairment Anxiety Must have excessive worry or anxiety most days for 6 months Must include worry in more than one event or activity Must be associated with a sense of lack of control Must have at least three associated symptoms Edginess, fatigue, poor concentration, irritability, muscle tension, sleep issues Must cause impairment 4
5 DSM Generalized Anxiety Disorder Social Anxiety Disorder Panic Disorder Separation Anxiety Disorder School Avoidance Obsessive Compulsive Disorder Selective Mutism PTSD Major Depression Disruptive Mood Dysregulation Disorder Persistent Depressive Disorder Cams study: Child/adol Anxiety Multimodal Study Randomized control trial with year old subjects GAD, Social phobia, Separation Anxiety CBT, sertraline, both, placebo Combined therapies had higher rates of remission Both CBT and med group had higher rates of remission than placebo In subjects who responded at 12 weeks the response was maintained at 24 and 36 weeks Treatment of Adolescent Depression: TADS Randomized controlled trial in 13 academic sites 327 subjects between the ages of Compared fluoxetine, CBT, and fluoxetine with CBT CBT alone was less effective than combined treatment or fluoxetine and not significantly more effective than placebo at week 12 Combined treatment increased the speed of the response, quality of life, remission and overall safety, primarily by preventing treatment emergent suicidality CBT benefit caught up with fluoxetine at week 18 All treatments were equally effective at 80% rate by week 36 The longer the treatment in TADS the more persistent the benefits over one year of naturalistic follow-up Literature Literature Strawn, JAACAP, October 2016 Meta-analysis of randomized placebo controlled trials of and SNRI s 1612 children and adolescents GAD, Social anxiety, Separation anxiety SNRI s and had a moderate effect size in reducing anxiety symptoms No difference in efficacy Strawn et al., JAACAP 4/2015 Randomized Placebo controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder 7-17 years old, GAD, mg duloxetine 135 medication group, 135 placebo Medication gourd was statistically significantly improved 5
6 Pearls For You So you Made the Diagnosis The first line treatment for both mild to moderate depression or anxiety is appropriate therapy The degree of functional impairment is the best measure of severity of symptoms treat both anxiety and depression equally well Treatment with medications must be at an adequate dose for an adequate length of time If the symptoms are mild to moderate start with therapy Educate the patient about the disorder, therapy resources and the expected timeline for improvement Have a follow-up in 4-6 weeks to ensure they have started therapy. Ask specific questions about the relationship with the therapist, the process of therapy, the goals of therapy Does the patient feel better? Practical Treatment Advice ELEMENTS OF COGNITIVE BEHAVIORAL THERAPY Primary medications /SNRI s Buspirone (GAD only) Secondary options Benzodiazepines Tricyclics How to Choose a Medication Medication decisions are first line All have same potential efficacy Choose based on side effect profile Individuals may have an idiosyncratic benefit to one SSRI and not another This may be influenced by metabolism differences Consider second choice dependent on diagnosis as well as safety and side effects of medication Depression Choose SSRI number one If no benefit switch to SSRI number two Must be from a different cytochrome P450 class If no benefit after two try buproprion If partial benefit and dose is maximized augment SSRI with buproprion If still no benefit change to venlafaxine Refer Anxiety Choose SSRI number one Switch to SSRI number two DO NOT USE BUPROPRION Switch to venlafaxine Consider buspar in generalized anxiety Consider clomipramine if OCD Avoid benzodiazepines Refer 6
7 Metabolism Considerations Fluoxetine (Prozac): 2.5 mg-80 mg Paroxetine (Paxil): 2.5 mg-60 mg Sertraline (Zoloft): 12.5 mg-200 mg Fluvoxamine (Luvox) 25 mg-300 mg Citalopram (Celexa) 10 mg-60 mg Escitalopram (Lexapro) 5 mg-30 mg Fluoxetine and paroxetine P450 2D6 Citalopram/escitalopram P450 C19 Sertraline P450 C9, C19, 2D6, 3A4 Venlafaxine P450 2D6, 3A4 Duloxetine P450 2D6, 1A2 Common side effects Akathisia (restlessness) Insomnia Nausea/Diarrhea Headache Sedation (not usual) Weight gain (minimal) Sexual dysfunction (60%) Half-life Fluvoxamine ~ hours Sertraline and Paroxetine ~ 24 hours Citalopram ~ 33 hours Fluoxetine ~ 2-3 days Norfluoxetine ~7-8 days SSRI withdrawal Paroxetine probably the worst Does not happen with fluoxetine Characterized by flu-like syndrome Fever, shaking, fatigue, sweating, nausea, diarrhea Usually starts within hours and resolves within 2-3 days, although may last longer Treat by restarting medication and slowing down the taper 7
8 Serotonin syndrome Can happen with any SSRI, as well as other me serotonergic effect such as venlafaxine, clomipramine, fenfluramine Rapid onset Symptoms related to flood of extracellular 5HT May be frightening for the patient trembling, shivering, fever, chills, clonus, hyperreflexia, may seem ataxic Treat with support and 5HT blockers cyproheptadine and chlorpromazine Buspirone Good for generalized anxiety but not for other forms of anxiety Needs twice daily and sometimes three times daily dosing making compliance with an adolescent problematic Common side effects: nausea, headache, mild fatigue Easy to taper off if ineffective Typical dose mg in divided doses Bupropion Venlafaxine Can be used alone or to augment a partial responder to an SSRI Most common side effects Headache, decreased appetite, agitation/activation Start with Buproprion XL 150 mg, increase to 300 mg after two weeks if no benefit Can be started and stopped abruptly with little risk of problems Contraindicated if seizure disorder is present or very high risk for seizures Common side effects: sedation, sexual dysfunction, restlessness, insomnia, weight gain MUST be slowly tapered if discontinuing Start with XR formulation at 75 mg. If there is a history of significant sensitivity to consider starting at 37.5 mg XR Usual dose is mg General medication issues All take 4-6 weeks for full benefit Do NOT continue medications if there is not clear objective evidence of benefit Treat depression for 9-12 months if medications are beneficial Treatment of anxiety is of variable length depending on the benefit from adjunctive therapy and individual circumstances Call your friendly mental health colleague for hand holding advice when needed 8
Depression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationManagement Of Depression And Anxiety
Management Of Depression And Anxiety CME Financial Disclosure Statement I, or an immediate family member including spouse/partner, have at present and/or have had within the last 12 months, or anticipate
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationDisclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017
Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More information2/23/18. Age of Anxiety: Transforming Qualms into Calm. Disclosures. Objectives. I have nothing to disclose
Age of Anxiety: Transforming Qualms into Calm Rosa Kim, MD Assistant Professor and Attending Child Psychiatrist Medical College of Wisconsin and Children s Hospital of Wisconsin Disclosures I have nothing
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationOverview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders
1 Learning Objectives 1. Providers will become familiar with methods of screening for depression and anxiety. 2. Providers will become more comfortable with diagnosis and management of these common pediatric
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationWomen, Mental Health, and HIV
Women, Mental Health, and HIV Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What is Mental Health? Refers to emotional, psychological, social
More informationMar 6, The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly
Mar 6, 2017. The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly effective treatment for the symptoms of PMS and PMDD. The
More informationShort Clinical Guidelines: General Anxiety Disorder (GAD)
Definition is one of the most prevalent psychiatric disorders seen in the primary care office and is characterized by excessive anxiety and worry about a number of events that cause clinically significant
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationHow to Manage Anxiety
How to Manage Anxiety Dr Tony Fernando Psychological Medicine University of Auckland Auckland District Health Board www.insomniaspecialist.co.nz www.calm.auckland.ac.nz Topics How to diagnose How to manage
More informationTreatment of Pediatric Anxiety Disorders in the Primary Care Setting. June 23, 2018 Aditi Sharma, MD
Treatment of Pediatric Anxiety Disorders in the Primary Care Setting June 23, 2018 Aditi Sharma, MD Imagine your anxious trigger Anxiety is Normal (to a degree) Protective Powerful Trigger Anxious reactivity
More informationManaging Anxiety Disorder in Primary Care
Saturday General Session Managing Anxiety Disorder in Primary Care Chris Ticknor, MD Private Practice, Psychiatry Adjunct Professor of Psychiatry UT Health Science Center at San Antonio San Antonio, Texas
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationGuideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians
MAGELLAN BEHAVIORAL HEALTH/ BLUE CROSS BLUE SHIELD OF NORTH CAROLINA Guideline for the Diagnosis and Management of Generalized Anxiety Disorder for Primary Care Physicians This guideline includes recommendations
More informationMedications Guide: Public Speaking And Social Anxiety
AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationJoe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health
Joe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health Solutions, PLLC www.bartoncbt.com Academic and Pop-Culture
More informationLet s Talk About Treatment
What Doesn t Work Let s Talk About Treatment Lisa R. Terry, LPC What we ve tried Talk therapy- You can t talk you way out of a medical disorder Play Therapy Family Therapy Psychoanalysis While these are
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationDepression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms
Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)
More informationCHILDHOOD/ADOLESCENT ANXIETY DISORDERS: EVALUATION AND TREATMENT
CHILDHOOD/ADOLESCENT ANXIETY DISORDERS: EVALUATION AND TREATMENT PHILIP L. BAESE, MD ASSISTANT PROFESSOR OF PSYCHIATRY CHIEF, DIVISION OF CHILD AND ADOLESCENT PSYCHIATRY UNIVERSITY OF UTAH, SCHOOL OF MEDICINE
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More information2/9/2016. Anxiety. Early Intervention for childhood Mental Health issues. ANXIETY DISORDERS in Children and Adolescents.
ANXIETY DISORDERS in Children and Adolescents. Joy Lauerer DNP PMHCNS BC Discussion Points Anxiety Early Intervention for childhood Mental Health issues Why? Important to long term health outcomes! What
More informationAn Overview of Anxiety and Mood Disorders in Youth
An Overview of Anxiety and Mood Disorders in Youth Mary Kay Nixon MD FRCPC Clinical Associate Professor, UBC Affliliate Associate Professor, UVic Family Physicians Conference February 22, 2012 Victoria,
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationAbnormal Child Psychology, 3rd Edition, Eric J. Mash, David A. Wolfe Chapter 7: Anxiety Disorders. Anxiety Disorders
Anxiety Disorders Experiencing Anxiety Anxiety: characterized by strong negative emotion and tension in anticipation of future danger or threat Moderate amounts of anxiety is adaptive; helps us cope with
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationWhat You Need to Know About Benzodiazepines & Other Anxiety Drugs
Anxiety Medication What You Need to Know About Benzodiazepines & Other Anxiety Drugs When you re overwhelmed by heartpounding panic, paralyzed by fear, or exhausted from yet another sleepless night spent
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Recognizing OCD and Anxiety Disorders in Children Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Epocrates Research
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationAnxiety in Youth: Identification, Management, & Referral
Anxiety in Youth: Identification, Management, & Referral Martin E. Franklin, Ph.D. Associate Professor of Psychiatry University of Pennsylvania School of Medicine Prelude to the Talk: Anxiety & Its Disorders
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More informationAnxiety. Definition. Sometimes anxiety results from a medical condition that needs treatment. Whatever form of anxiety you have, treatment can help.
Anxiety Definition Experiencing occasional anxiety is a normal part of life. However, people with anxiety disorders frequently have intense, excessive and persistent worry and fear about everyday situations.
More informationPharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests
Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San
More informationDOWNLOAD OR READ : SOCIAL ANXIETY IN CHILDHOOD BRIDGING DEVELOPMENTAL AND CLINICAL PERSPECTIVES PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : SOCIAL ANXIETY IN CHILDHOOD BRIDGING DEVELOPMENTAL AND CLINICAL PERSPECTIVES PDF EBOOK EPUB MOBI Page 1 Page 2 social anxiety in childhood bridging developmental and clinical perspectives
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationDepression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:
Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationPsychiatric Treatment of the Concussed Athlete
Psychiatric Treatment of the Concussed Athlete Eastern Athletic Trainers Association January 11 th, 2015 Alexander S. Strauss, MD Centra, P.C. E-MAIL: DRSTRAUSS@ALEXSTRAUSSMD.COM Evidence Mounts Linking
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationAssessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH
Assessing and Treating Depression and Anxiety in Children with Cancer Anna (Nina) Muriel, MD, MPH Chief, Division of Pediatric Psychosocial Oncology Department of Psychosocial Oncology and Palliative Care
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationBe a Warrior, Not a Worrier: Anxiety Disorders in the Pediatric Setting
Be a Warrior, Not a Worrier: Anxiety Disorders in the Pediatric Setting Ramon Solhkhah, M.D. Professor and Founding Chair, Department of Psychiatry & Behavioral Health Hackensack Meridian School of Medicine
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationSICKNESS AND HEALTH III. The following anxiety disorders are discussed on this website:
SICKNESS AND HEALTH III 8.1 CLINICAL ANXIETY AND HEALTH: Anxiety is a normal reaction to stress and can actually be beneficial in some situations. For some people, however, anxiety can become excessive.
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationMental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling
Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2012 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationFortunately, panic disorder is one of the most treatable anxiety disorders. The illness can be controlled with medication and focused psychotherapy.
Anxiety Disorders Anxiety disorders are the most common mental illness in America. More than 19 million Americans suffer from anxiety disorders, which include panic disorder, obsessive-compulsive disorder,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Update: 2013 I have nothing to disclose Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California,
More informationMore Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School
More Than Just Moody Blaise Aguirre, MD Child and Adolescent Psychiatrist McLean Hospital Assistant Professor of Psychiatry Harvard Medical School Keep in Mind In the U.S., approximately 10-15% of children/adolescents
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationSUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,
More informationGeneralized anxiety disorder
1 of 6 3/24/2007 4:07 PM Original Article:http://www.mayoclinic.com/health/generalized-anxiety-disorder/DS00502 Generalized anxiety disorder Introduction It's normal to feel anxious or worried at times.
More informationDiabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C
Diabetes and Depression Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C 2008 Learning Objectives State the risk factors for depression Identify the vulnerability
More informationUsing Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University
Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%
More informationPrimary Care Psychopharmacology for Anxiety Disorders. Holly Ellison, RN, MSN, PMHNP-BC Board Certified Psychiatric Mental Health Nurse Practitioner
Primary Care Psychopharmacology for Anxiety Disorders Holly Ellison, RN, MSN, PMHNP-BC Board Certified Psychiatric Mental Health Nurse Practitioner Prevalence of Any Anxiety Disorder Among U.S. Adults
More informationJonathan Haverkampf PANIC ATTACKS PANIC ATTACKS. Christian Jonathan Haverkampf MD
Christian MD Panic attacks can be highly debilitating as they occur spontaneously and come with a dread of impending doom and often death. Their unpredictability and the strong feelings of anxiety can
More informationGeneralized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6
Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control.
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationConsequences of Anxiety. Common Difficulties Due to Anxiety and How Post-Secondary Educators Can Help. Slide 1
1 Common Difficulties Due to Anxiety and How Post-Secondary Educators Can Help Julie L. Ryan, Ph.D. Assistant Professor of Psychology Fairleigh Dickinson University 2 Facts about Anxiety Disorders Anxiety
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationAverage dose zoloft for ocd and anxiety
Average dose zoloft for ocd and anxiety Gogamz Menu DESCRIPTION. Selective serotonin reuptake inhibitor (SSRI). Approved for depression, OCD, panic disorder, PTSD, premenstrual-dysphoric disorder (PMDD),
More informationYour Anxious Child: What Parents Need to Know. Caryl Oris, MD
Your Anxious Child: What Parents Need to Know Caryl Oris, MD What s Normal? n Normal developmental fears: n Separation Anxiety n Fear of the dark n Separation Anxiety n Fear is a physiological reaction
More informationTreating Anxiety Disorders. Adil Virani, BSc (Pharm), Pharm D, FCSHP
Treating Anxiety Disorders Adil Virani, BSc (Pharm), Pharm D, FCSHP Outline! Michelle s Case! Types of anxiety disorders! Goals of therapy! Treatment options and guidelines! Pharmacological options! Benzodiazepines
More informationAnxiety Disorders: First aid and when to refer on
Anxiety Disorders: First aid and when to refer on Presenter: Dr Roger Singh, Consultant Psychiatrist, ABT service, Hillingdon Educational resources from NICE, 2011 NICE clinical guideline 113 What is anxiety?
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationDepression & Suicide 7/11/2017 DISCLOSURES. DSM 5 Depressive Disorders. Objectives
DISCLOSURES Depression & Suicide July 19, 2017 GenaLynne C. Mooneyham, MD, MS Pediatrics/Psychiatry/Child & Adolescent Psychiatry No financial disclosures There may be discussion of off label medication
More informationEffective Strategies for Helping Distressed / Anxious Children and Teens Webinar Handout 8/27/2010
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 True or False Test Anxiety disorders rank first as the most common mental health issue with young people. Up to 40 million people are affected with significant anxiety.
More informationPartners in Care Quick Reference Cards
Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly
More information